{"title":"RCN1影响弥漫大b细胞淋巴瘤的恶性进展和巨噬细胞M2极化。","authors":"Qiuyu Zhu , Xiafang Yang","doi":"10.1016/j.mcp.2025.102042","DOIUrl":null,"url":null,"abstract":"<div><div>Malignant behaviors of cancer cells and immune evasion by macrophage can lead to treatment failure in diffuse large B-cell lymphoma (DLBCL). Recent studies have revealed the aberrant expression of reticulocalbin 1 (RCN1) that is associated with malignant progression of several cancers. Nevertheless, its roles in DLBCL remain unclear. In this present study, several online bioinformatics databases substantiated high expression of RCN1 in tumor samples from DLBCL patients. Furthermore, there were obvious elevation of RCN1in tumor specimens form our collected tissues and DLBCL cells. Importantly, the shorter survival outcome was observed in patients with high levels of RCN1. Intriguingly, down-regulation of RCN1 attenuated DLBCL cell viability, invasion ability and increased cancer cell apoptosis. Moreover, TIMER database revealed the correlation between RCN1 expression and tumor-infiltrating macrophages, and M2 macrophage markers in DLBCL patients. Knockdown of RCN1 suppressed cancer cell ability to induce macrophage M2-like polarization by inhibiting the percentage of CD163<sup>+</sup> macrophages and expression of M2-like markers (CD163, CD204, and IL-10). Concomitantly, M2 macrophage-induced cancer cell viability and invasion was abrogated after RCN1 down-regulation. Further assay revealed that knockdown of RCN1 suppressed activation of the PI3K/AKT signaling in DLBCL cells. Notably, reactivation this pathway via its agonist 740Y-P offset the anti-tumor efficacy of RCN1 knockdown in cancer cell malignancy and macrophage polarization towards M2 phenotype. Therefore, RCN1 may contribute to the malignant progression of DLBCL by directly regulating cancer cell behavior and indirectly affecting macrophage M2-like polarization, supporting it as a promising therapeutic target against DLBCL.</div></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":"83 ","pages":"Article 102042"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RCN1 affects malignant progression and macrophage M2 polarization in diffuse large B-cell lymphoma\",\"authors\":\"Qiuyu Zhu , Xiafang Yang\",\"doi\":\"10.1016/j.mcp.2025.102042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Malignant behaviors of cancer cells and immune evasion by macrophage can lead to treatment failure in diffuse large B-cell lymphoma (DLBCL). Recent studies have revealed the aberrant expression of reticulocalbin 1 (RCN1) that is associated with malignant progression of several cancers. Nevertheless, its roles in DLBCL remain unclear. In this present study, several online bioinformatics databases substantiated high expression of RCN1 in tumor samples from DLBCL patients. Furthermore, there were obvious elevation of RCN1in tumor specimens form our collected tissues and DLBCL cells. Importantly, the shorter survival outcome was observed in patients with high levels of RCN1. Intriguingly, down-regulation of RCN1 attenuated DLBCL cell viability, invasion ability and increased cancer cell apoptosis. Moreover, TIMER database revealed the correlation between RCN1 expression and tumor-infiltrating macrophages, and M2 macrophage markers in DLBCL patients. Knockdown of RCN1 suppressed cancer cell ability to induce macrophage M2-like polarization by inhibiting the percentage of CD163<sup>+</sup> macrophages and expression of M2-like markers (CD163, CD204, and IL-10). Concomitantly, M2 macrophage-induced cancer cell viability and invasion was abrogated after RCN1 down-regulation. Further assay revealed that knockdown of RCN1 suppressed activation of the PI3K/AKT signaling in DLBCL cells. Notably, reactivation this pathway via its agonist 740Y-P offset the anti-tumor efficacy of RCN1 knockdown in cancer cell malignancy and macrophage polarization towards M2 phenotype. Therefore, RCN1 may contribute to the malignant progression of DLBCL by directly regulating cancer cell behavior and indirectly affecting macrophage M2-like polarization, supporting it as a promising therapeutic target against DLBCL.</div></div>\",\"PeriodicalId\":49799,\"journal\":{\"name\":\"Molecular and Cellular Probes\",\"volume\":\"83 \",\"pages\":\"Article 102042\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular and Cellular Probes\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0890850825000350\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890850825000350","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
RCN1 affects malignant progression and macrophage M2 polarization in diffuse large B-cell lymphoma
Malignant behaviors of cancer cells and immune evasion by macrophage can lead to treatment failure in diffuse large B-cell lymphoma (DLBCL). Recent studies have revealed the aberrant expression of reticulocalbin 1 (RCN1) that is associated with malignant progression of several cancers. Nevertheless, its roles in DLBCL remain unclear. In this present study, several online bioinformatics databases substantiated high expression of RCN1 in tumor samples from DLBCL patients. Furthermore, there were obvious elevation of RCN1in tumor specimens form our collected tissues and DLBCL cells. Importantly, the shorter survival outcome was observed in patients with high levels of RCN1. Intriguingly, down-regulation of RCN1 attenuated DLBCL cell viability, invasion ability and increased cancer cell apoptosis. Moreover, TIMER database revealed the correlation between RCN1 expression and tumor-infiltrating macrophages, and M2 macrophage markers in DLBCL patients. Knockdown of RCN1 suppressed cancer cell ability to induce macrophage M2-like polarization by inhibiting the percentage of CD163+ macrophages and expression of M2-like markers (CD163, CD204, and IL-10). Concomitantly, M2 macrophage-induced cancer cell viability and invasion was abrogated after RCN1 down-regulation. Further assay revealed that knockdown of RCN1 suppressed activation of the PI3K/AKT signaling in DLBCL cells. Notably, reactivation this pathway via its agonist 740Y-P offset the anti-tumor efficacy of RCN1 knockdown in cancer cell malignancy and macrophage polarization towards M2 phenotype. Therefore, RCN1 may contribute to the malignant progression of DLBCL by directly regulating cancer cell behavior and indirectly affecting macrophage M2-like polarization, supporting it as a promising therapeutic target against DLBCL.
期刊介绍:
MCP - Advancing biology through–omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.